News
Better Buy: AbbVie Inc. vs. Johnson & Johnson
They're partners. And they're rivals. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. However, the two big drugmakers compete against each....
3 Stocks That Have Doubled and Still Have Room to Grow
The S&P 500 is hovering near an all-time high and has had a great year in 2017, so it's not a surprise that many stocks have delivered exceptional performance recently. However, just because a....
Is Merck & Co. Inc. a Buy?
If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of....
3 Biotech Stocks to Be Thankful for This Year
Anyone who has been holding onto shares of Loxo Oncology Inc. (NASDAQ: LOXO), Nektar Therapeutics (NASDAQ: NKTR), or Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) will have plenty to say when it's....
3 Biotech Stocks That Soared: Are They Buys?
Some of the biggest moves week in and week out come from biotech stocks. Whether it's a financial surprise, a positive clinical-trial update, regulatory approval, or even just rumors of....
What’s Next for Nektar Therapeutics?
Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses....
Is Loxo Oncology's Deal With Bayer Bad News?
After reporting that global biopharma giant Bayer AG (NASDAQOTH: BAYRY) has inked a licensing deal for its most advanced clinical-stage drug, shares in Loxo Oncology (NASDAQ: LOXO) tumbled. Is....
Better Buy: Biogen Inc. vs. Gilead Sciences
Historically, Biogen (NASDAQ: BIIB) has definitely been a better stock than Gilead Sciences (NASDAQ: GILD). Whether you look at the last three, five, 10, 25 years, or even so far in 2017, Biogen....
3 Reasons Novavax Stock Could Double in 2018
Charles Dickens' introduction to A Tale of Two Cities sort of applies to Novavax's (NASDAQ: NVAX) experience in 2017 so far: "It was the best of times, it was the worst of times..."At two....
Why Vascular Biogenics Ltd. Is Tanking Today
After the company released the pricing details of its just-announced common stock offering, shares of Vascular Biogenics (NASDAQ: VBLT), a clinical-stage biotech focused on cancer, fell 18% as of....
Medigene: Unter 10 EUR? Ist doch super!
Die Anteile des Biotechnologieunternehmens Medigene zeigen in diesem Jahr riesige Kursausschläge. Von 30 bis 70 Prozent nach oben und von 30 bis 45 Prozent nach unten ist fast alles dabei. Allein....
Can This Tiny Biotech Stock Pay Off Big for Celgene?
Celgene Corp (NASDAQ: CELG) loves cozying up to emerging biotech stocks working on next-generation medicine, and one of those collaborations is with Jounce Therapeutics (NASDAQ: JNCE). Celgene....
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
After Achillion Pharmaceuticals (NASDAQ: ACHN) priced its shares that Johnson & Johnson (NYSE: JNJ) is selling at $2.75 each, the company is rallying back 19.5% as of 3:15 p.m. EST.Johnson....
Genomic Health, Inc. Turns a Profit (With an Asterisk)
Genomic Health (NASDAQ: GHDX) recorded a $1.1 million profit during the third quarter, something it's been shooting for as it's improved its bottom line for each of the last nine consecutive....
Here's Why Nektar Therapeutics Is Skyrocketing 70% in November
After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, Nektar Therapeutics....
Where Will Aurinia Pharmaceuticals Be in 5 Years?
Predicting the future isn't hard at all. Predicting the future accurately is a different matter altogether.I wanted to state that at the outset before attempting to predict how things will unfold....
Is Opko Health Inc. a Buy?
Longtime Opko Health Inc. (NASDAQ: OPK) shareholders have a lot to be upset about. Using about $1.47 billion of its own stock to acquire a big lab service provider a couple years ago was supposed....
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
What's the best big pharma stock?Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others.....
Here's Why Sangamo Therapeutics Rose as Much as 16.3% Today
Shares of Sangamo Therapeutics (NASDAQ: SGMO) rose over 16% today after the company announced that the first patient had been dosed in a phase 1/2 trial evaluating the potential for its....
Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3....
Here's Why Acorda Therapeutics Got Crushed Today
Shares of biopharma Acorda Therapeutics (NASDAQ: ACOR) dropped as much as 40.1% Wednesday after the company issued an update on its second-leading drug candidate. The company is increasing the....
Why Achillion Pharmaceuticals Stock Is Falling Today
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are falling hard today after the company announced that Johnson & Johnson (NYSE: JNJ) has decided to sell 18.4 million of the drugmaker's....
Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings
Shares of synthetic biology conglomerate Intrexon (NYSE: XON) were crushed following the release of third-quarter 2017 earnings last week. Although missing Wall Street's revenue expectations....
QUANTUM GENOMICS : Recrutement aux Etats-Unis des premiers patients de l'étude NEW-HOPE dans l'hypertension artérielle
Communiqué de presse
Paris, le 15 novembre 2017
Une étude menée aux Etats-Unis pour un meilleur ciblage
NEW-HOPE : un essai clinique de phase II récompensé par le prix Galien....
